ArticleApplied and environmental microbiology2001
Secretion of active recombinant human tissue plasminogen activator derivatives in Escherichia coli.
Article in Applied and environmental microbiology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 37 citations in OpenAlex.
- Response Surface Methodology to Optimize the Expression Efficiency of Recombinant Reteplase.Iranian journal of biotechnology · 2023Article
- Reteplase: Structure, Function, and Production.Advanced biomedical research · 2019Review
- Soluble expression, purification, and characterization of active recombinant human tissue plasminogen activator by auto-induction in E. coli.BMC biotechnology · 2015Article
- Proteomic study of the brackish water musselZoological studies · 2015Article
- Molecular cloning of Reteplase and its expression in E. coli using tac promoter.Advanced biomedical research · 2014Article
- Cloning and Expression of Functional Reteplase in Escherichia coli TOP10.Avicenna journal of medical biotechnology · 2013Article
- Expression of the recombinant plasminogen activator (reteplase) by a non-lytic insect cell expression system.Research in pharmaceutical sciences · 2013Article
- Expression of active recombinant human tissue-type plasminogen activator by using in vivo polyhydroxybutyrate granule display.Applied and environmental microbiology · 2010Article
- Blockade of CD28 by a synthetical peptoid inhibits T-cell proliferation and attenuates graft-versus-host disease.Cellular & molecular immunology · 2010Article
- Expression of a novel chimeric truncated t-PA in CHO cells based on in silico experiments.Journal of biomedicine & biotechnology · 2010Article
- Asn and asn: critical residues for in vitro biological activity of reteplase.Advances in hematology · 2010Article
- Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins.Microbial cell factories · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The DNA fragment coding for kringle 2 plus serine protease domains (K2S) of tissue plasminogen activator (tPA) was inserted into a phagemid vector, pComb3HSS. In the recombinant vector, pComb3H-K2S, the K2S gene was fused to gpIII of PhiM13 and linked to the OmpA signal sequence. The resulting gene, rK2S-gpIII, was inducibly expressed in Escherichia coli XL-1 Blue. The protein was presented on the phage particle. To stop the expression of gpIII, a stop codon between K2S and the gpIII gene was inserted by site-directed mutagenesis. This mutated vector, MpComb3H-K2S, was transformed in XL-1 Blue. After induction with IPTG (isopropyl-beta-D-thiogalactopyranoside), rK2S was found both in the periplasm as an inactive form of approximately 32% and in the culture supernatant as an active form of approximately 68%. The secreted form of rK2S was partially purified by ammonium sulfate (55%) precipitation. The periplasmic form was isolated from whole cells by chloroform extraction. The fibrin binding site of kringle 2 was demonstrated in all expressed versions (phage-bound, periplasmic, and secreted forms) using the monoclonal anti-kringle 2 antibody (16/B). Only the secreted form of rK2S revealed a fibrinogen-dependent amidolytic activity with the specific activity of 236 IU/microg. No amidolytic activity of rK2S was observed in either the periplasmic or the phage-bound form. The secretion of rK2S as an active enzyme offers a novel approach for the production of the active-domain deletion mutant tPA, rK2S, without any requirements for bacterial compartment preparation and in vitro refolding processes. This finding is an important technological advance in the development of large-scale, bacterium-based tPA production systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.